Gentian Diagnostics ASA (OSL:GENT)

Market Cap	891.41M +43.8%
Revenue (ttm)	172.52M +17.4%
Net Income	42.78M +1,826.9%
EPS	2.75 +1,810.5%
Shares Out	15.42M
PE Ratio	21.02
Forward PE	56.12
Dividend	0.40 (0.69%)
Ex-Dividend Date	n/a

Volume	40
Average Volume	13,942
Open	57.80
Previous Close	57.80
Day's Range	57.80 - 57.80
52-Week Range	41.00 - 65.80
Beta	0.44
RSI	51.19
Earnings Date	Feb 11, 2026

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chro...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 63
• Stock Exchange: Oslo Børs
• Ticker Symbol: GENT